Silence Therapeutics (SLN) Profit After Tax (2024 - 2026)

Silence Therapeutics has reported Profit After Tax for 3 years, with the latest figure at -$15.0 million in Q1 2026.

• Quarterly Profit After Tax rose 47.42% year-over-year to -$15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$75.1 million (down 5.01% YoY) and the FY2025 annual result came in at -$88.6 million, down 95.55% from the prior year.
• Profit After Tax eased to -$15.0 million in Q1 2026 per SLN's latest filing, from -$11.8 million in the prior quarter.
• Over five years, Profit After Tax peaked at $12.3 million in Q4 2024 and troughed at -$35.5 million in Q3 2024.
• A 3-year average of -$16.6 million and a median of -$19.8 million in 2024 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2025 and 2026: Profit After Tax tumbled 1134.0% in 2025, then surged 47.42% in 2026.
• Over 3 years, Profit After Tax stood at $12.3 million in 2024, then slumped by 195.92% to -$11.8 million in 2025, then declined by 27.12% to -$15.0 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$15.0 million, -$11.8 million, and -$21.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.